If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Members of the parliament of the Free State would be required to take an oath of allegiance to the Constitution of the Free State and to declare that they would be "faithful" to the king (a modification of the oath taken in other dominions). The Second Dáil ratified the Treaty on 7 January 1922, causing a split in the republican movement. A Provisional Government was formed, with Michael Collins as chairman. The Free State was established on 6 December 1922, and the Provisional Government became the Executive Council of the Irish Free State, headed by W. T. Cosgrave as President of the Executive Council. The following day, the Commons and the Senate of Northern Ireland passed resolutions "for the express purpose of opting out of the Free State". Two days after the founding of the Irish Free State, anti-Treaty IRA members opened fire on Seán Hales and Pádraic Ó Máille, both Teachtaí Dála (TDs), as they were leaving the Dáil. Hales was killed, while Ó Máille was seriously wounded. On 8 December 1922, four imprisoned leaders of the anti-treaty IRA (Liam Mellows, Rory O'Connor, Joe McKelvey and Dick Barrett) were executed in retaliation for the killing of Hales.
== Distribution and habitat == Coffee senna is native to the southern United States of America, Mexico and South America, but is an aggressive, pantropical weed. In Australia it is widespread but scattered in the north of Western Australia, the Northern Territory, South Australia, Queensland and New South Wales.
Recreational users sometimes open dexedrine capsules and crush the contents in order to insufflate (snort) it or subsequently dissolve it in water and inject it. Immediate-release formulations have higher potential for abuse via insufflation (snorting) or intravenous injection due to a more favorable pharmacokinetic profile and easy crushability (especially tablets). Injection into the bloodstream can be dangerous because insoluble fillers within the tablets can block small blood vessels. Chronic overuse of dextroamphetamine can lead to severe drug dependence, resulting in withdrawal symptoms when drug use stops.
=== Normal function === Cyclin D1 was originally cloned as a breakpoint rearrangement in parathyroid adenoma and was shown to be required for progression through the G1 phase of the cell cycle to induce cell migration, angiogenesis and to induce the Warburg effect. Cyclin D1 is a protein required for progression through the G1 phase of the cell cycle. During the G1 phase, it is synthesized rapidly and accumulates in the nucleus, and is degraded as the cell enters the S phase. Cyclin D1 is a regulatory subunit of cyclin-dependent kinases CDK4 and CDK6. The protein dimerizes with CDK4/6 to regulate the G1/S phase transition and entry into the S-phase.
Sources: en.wikipedia.org
Relatedly, DFNZ shows diminished efficacy in activating the MOR–galanin receptor 1 (MOR–GAL1) heteromer and has limited effects on dopaminergic signaling in the nucleus accumbens. Based on preclinical findings, the drug has low expected misuse liability in humans. It remains unclear the extent to which the analgesia of DFNZ is mediated by central versus peripheral MORs. However, it is known that the peripherally restricted MOR agonist loperamide shows only weak analgesic effects, in contrast to the strong analgesia of DFNZ. DFNZ is described as having an unusually strong and favorable safety profile for an opioid analgesic, let alone for a high-efficacy nitazene opioid. DFNZ was first described in the scientific literature by 2026. It was developed by researchers at the National Institute on Drug Abuse (NIDA) and other institutions. There is interest in DFNZ for potential medical use as an analgesic in the treatment of pain and in opioid maintenance therapy. The drug may have advantages over conventional opioids such as improved safety. Sustained-release formulations may be required for some indications, like opioid substitution. DFNZ is a potential novel designer drug, but has not yet been encountered as one as of May 2026.
Neoplasm: benign or malignant Granuloma: tuberculosis Infection: round pneumonia Vascular: infarct, varix, granulomatosis with polyangiitis, rheumatoid arthritis There are a number of features that are helpful in suggesting the diagnosis:
=== Venous drainage === Unlike most of the myocardium, the SA node lacks large epicardial veins for blood return. Instead, its venous drainage is handled primarily by a network of small venules and sinusoids. These vessels, often referred to as Thebesian veins, drain deoxygenated blood directly into the right atrium. It is thought that this network provides a degree of protection for the node. This is because the vessels communicate with the nodal tissue and may help maintain viable conditions if the primary arterial supply is partially compromised.
The U.S. Department of Energy (DOE) has published a list of yearly technical system targets for on-board hydrogen storage for light-duty fuel cell vehicles which guide researchers in the field (5.5 wt %/40 g L−1 by 2017; 7.5 wt %/70 g L−1 ultimate). Materials with high porosity and high surface area such as MOFs have been designed and synthesized in an effort to meet these targets. These adsorptive materials generally work via physical adsorption rather than chemisorption due to the large HOMO–LUMO gap and low HOMO energy level of molecular hydrogen. A benchmark material to this end is MOF-177 which was found to store hydrogen at 7.5 wt % with a volumetric capacity of 32 g L−1 at 77 K and 70 bar. MOF-177 consists of [Zn4O]6+ clusters interconnected by 1,3,5-benzenetribenzoate organic linkers and has a measured BET surface area of 4630 m2 g−1. Another exemplary material is PCN-61 which exhibits a hydrogen uptake of 6.24 wt % and 42.5 g L−1 at 35 bar and 77 K and 2.25 wt % at atmospheric pressure. PCN-61 consists of [Cu2]4+ paddle-wheel units connected through 5,5′,5′′-benzene-1,3,5-triyltris(1-ethynyl-2-isophthalate) organic linkers and has a measured BET surface area of 3000 m2 g−1. Despite these promising MOF examples, the classes of synthetic porous materials with the highest performance for practical hydrogen storage are activated carbon and covalent organic frameworks (COFs).
On March 2, 1955, a group of executives from the delegations of the conference gathered at the Hall of Mirrors in the Presidential Palace, where they were received by President Fulgencio Batista. The group included the Grand Officers of the Grand Lodge of Cuba, the Grand Master of Cuba, and executive officers from CMI. Also present were Minister of Agriculture Andrés Domingo Morales del Castillo, and Fidel Barreto. They shook hands with Batista. Batista thanked them for their work, and praised the executives for the smooth success of the conference. President Batista offered his congratulations on the consecration of the Masonic Temple, and admitted that he thought it was "...a majestic structure rising on the city.... [it] stands as a source of legitimate pride not only for Cuban Freemasonry but for that of the entire American continent." Batista pledged that he would assist the Grand Lodge of Cuba wherever he could. He noted, "...in accordance with Masonic principles..." that his Presidential Administration would be dedicated to the preserving freedom of expression, the free interplay of ideas in society and in the economic spheres, fraternity among Cubans, and equality between men and women, regardless of class.
Sources: en.wikipedia.org
=== Wound dressings === There are many types of dressings used to treat diabetic foot ulcers, such as absorptive fillers, hydrogel dressings, and hydrocolloids. There is no good evidence that one type of dressing is better than another for diabetic foot ulcers. In selecting dressings for chronic non-healing wounds, it is recommended that the cost of the product be taken into account. Hydrogel dressings may have shown a slight advantage over standard dressings, but the quality of the research is of concern. Dressings and creams containing silver have not been properly studied nor have alginate dressings. Biologically active bandages that combine hydrogel and hydrocolloid traits are available; however, more research needs to be conducted as to the efficacy of this option over others.
== Pharmacokinetics == When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days. It has a relatively long half-life between 68 and 101 hours in Japanese subjects and between 82 and 130 hours in Caucasian subjects. Mavatrep is largely eliminated non-renally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.
== Further reading == Marshall JD, Beck S, Maffei P, Naggert JK (2007). "Alström syndrome". Eur. J. Hum. Genet. 15 (12): 1193–202. doi:10.1038/sj.ejhg.5201933. PMID 17940554. Alfonso Ortigado., et al. "Semaglutide in Alström Syndrome: An Improvement in the Natural Course of Cardiomyopathy". EC Paediatrics 14.7 (2025): 01-07. Berkower C. Voice of the Patient Report [Internet]. Alstrom Syndrome International; 2022 [cited 2024 Aug 22]. Available from: https://www.alstrom.org/wp-content/uploads/2023/05/ASI-EL-PFDD_FINAL_8May23.pdf Knorz VJ, Spalluto C, Lessard M, Purvis TL, Adigun FF, Collin GB, Hanley NA, Wilson DI, Hearn T (2010): Centriolar association of ALMS1 and likely centrosomal functions of the ALMS motif-containing proteins C10orf90 and KIAA1731. Mol Biol Cell (21):3617-3629. Koc E, Bayrak G, Suher M, Ensari C, Aktas D, Ensari A (2006): Rare case of Alstrom syndrome without obesity and with short stature, diagnosed in adulthood. Nephrology11(2):81-84. Roy A, Patel L, Yuan M, O'Shea C, Alvior AMB, Charalambides M, Moxon D, Baig S, Bunting KV, Gehmlich K, Geberhiwot T, Steeds RP. Defining the cardiovascular phenotype of adults with Alström syndrome. Int J Cardiol. 2024 Aug 15;409:132212. doi: 10.1016/j.ijcard.2024.132212. Epub 2024 May 26. PMID 38806112.
Also, alphaproteobacteria present a potentially large source of the lipid in the rock record. It has been suggested that these organisms may be synthesizing gammacerane in response to other shifting parameters during water column stratification, as most of the bacteria that contain the ths gene thrive in dynamic environments.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.